Cytocom, Inc. – NASDAQ:CBLI

Cytocom stock price today

$3.17
+2.94
+1287.92%
Financial Health
0
1
2
3
4
5
6
7
8
9

Cytocom stock price monthly change

-92.81%
month

Cytocom stock price quarterly change

-92.81%
quarter

Cytocom stock price yearly change

-95.03%
year

Cytocom key metrics

Market Cap
 226.38M
Enterprise value
 N/A
P/E
 -18.60
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 1124.25
Price/Book
 3.62
PEG ratio
 -1.06
EPS
 -0.16
Revenue
 N/A
EBITDA
 -2.30M
Income
 -2.31M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 -6043.51%
Oper. margin
 -6347.87%
Gross margin
 100%
EBIT margin
 -6347.87%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Cytocom stock price history

Cytocom stock forecast

Cytocom financial statements

Profit Margin

Cytocom, Inc. (NASDAQ:CBLI): Profit margin
Jun 2020 63.25K -369.83K -584.68%
Sep 2020 43.64K -745.38K -1707.84%
Mar 2021 0 -538.09K
Jun 2021 0 -659.50K
CBLI income statement history

Debt to Assets

Cytocom, Inc. (NASDAQ:CBLI): Debt to assets
Sep 2020 3231288 483.87K 14.97%
Dec 2020 2318021 304.61K 13.14%
Mar 2021 14699758 518.15K 3.52%
Jun 2021 13828734 300.62K 2.17%
CBLI balance sheet history

Cash Flow

Cytocom, Inc. (NASDAQ:CBLI): Cash Flow
Sep 2020 -682.65K -858 2.78M
Dec 2020 -788.32K 13.05K 0
Mar 2021 -363.09K 53.80K 12.72M
Jun 2021 -860.45K 269.30K 214
CBLI cash flow history

Cytocom alternative data

Cytocom
Employees

Cytocom, Inc. (NASDAQ:CBLI): Employee count
Aug 2023 18
Sep 2023 18
Oct 2023 18
Nov 2023 18
Dec 2023 18
Jan 2024 18
Feb 2024 18
Mar 2024 18
Apr 2024 18
May 2024 18
Jun 2024 18
Jul 2024 18

Cytocom other data

Cytocom
Insider Trading

Cytocom, Inc. (NASDAQ:CBLI): Insider trades (number of shares)
Period Buy Sel
Feb 2015 1891 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
MILLER LANGDON L officer: President & CMO
 Common Stock, par value $0.005 per share 10,000 $3 $30,000
Option
MILLER LANGDON L officer: President & CMO
 Employee Stock Option (right to buy) 10,000 $3 $30,000
Purchase
SALUCK RANDY S. director
 Common Stock, par value $0.005 per share 1,891 $3.42 $6,469
Purchase
DICORLETO PAUL E director
 Common Stock, par value $0.005 per share 6,210 $1.61 $9,998
Purchase
SALUCK RANDY S. director
 Common Stock, par value $0.005 per share 3,500 $1.6 $5,614
Purchase
ANTAL JAMES director
 Common Stock, par value $0.005 per share 3,700 $1.56 $5,772
Purchase
ANTAL JAMES director
 Common Stock, par value $0.005 per share 4,300 $1.35 $5,805
Purchase
ANTAL JAMES director
 Common Stock, par value $0.005 per share 2,316 $2.6 $6,022
Purchase
HOHN DAVID C director
 Common stock, par value $0.005 per share 1,000 $1.61 $1,610
Purchase
ANTAL JAMES director
 Common Stock, par value $0.005 per share 3,400 $1.76 $5,984
CBLI insider trading transactions

Cytocom
Patents

Patent
Application
Filling date: 5 Nov 2020 Issue date: 9 Sep 2021
Application
Filling date: 21 Jul 2020 Issue date: 10 Jun 2021
Grant
Filling date: 21 Nov 2018 Issue date: 8 Dec 2020
Grant
Filling date: 19 Feb 2019 Issue date: 22 Sep 2020
Application
Filling date: 19 Feb 2019 Issue date: 12 Sep 2019
CBLI patents

Cytocom
Earnings Call Transcripts

Quarter Transcript
Q2 2021 16 Aug 2021 Q2 2021 Earnings Call Transcript
Q3 2015 6 Nov 2015 Q3 2015 Earnings Call Transcript
Q2 2015 12 Aug 2015 Q2 2015 Earnings Call Transcript
Q1 2015 7 May 2015 Q1 2015 Earnings Call Transcript
CBLI earnings call transcripts

Frequently Asked Questions (FAQ)

  • What's the price of Cytocom stock today?

    One share of Cytocom stock can currently be purchased for approximately $3.17.

  • When is Cytocom's next earnings date?

    Unfortunately, Cytocom's (CBLI) next earnings date is currently unknown.

  • Does Cytocom pay dividends?

    No, Cytocom does not pay dividends.

  • How much money does Cytocom make?

    Cytocom has a market capitalization of 226.38M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 76.38% to 262.94K US dollars.

  • What is Cytocom's stock symbol?

    Cytocom, Inc. is traded on the NASDAQ under the ticker symbol "CBLI".

  • What is Cytocom's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Cytocom?

    Shares of Cytocom can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Cytocom have?

    As Jul 2024, Cytocom employs 18 workers.

  • When Cytocom went public?

    Cytocom, Inc. is publicly traded company for more then 19 years since IPO on 21 Jul 2006.

  • What is Cytocom's official website?

    The official website for Cytocom is cytocom.com.

  • Where are Cytocom's headquarters?

    Cytocom is headquartered at 73 High St, Buffalo, NEW YORK.

  • How can i contact Cytocom?

    Cytocom's mailing address is 73 High St, Buffalo, NEW YORK and company can be reached via phone at +1 716 849 6810.

Cytocom company profile:

Cytocom, Inc.

cytocom.com
Exchange:

NASDAQ

Full time employees:

18

Industry:

Biotechnology

Sector:

Healthcare

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

+1 716 849 6810
73 High St
Buffalo, NEW YORK

CIK: 0001318641
ISIN: US1858602022
CUSIP: 185860202